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Background: Immunomodulatory therapies have been identified as interventions for secondary injury after
traumatic brain injury (TBI). The cannabinoid receptor type-2 (CB2R) is proposed to play an important, endogenous
role in regulating inflammation. The effects of CB2R stimulation, blockade, and deletion on the neurovascular
inflammatory responses to TBI were assessed.
Methods: Wild-type C57BL/6 or CB2R knockout mice were randomly assigned to controlled cortical impact (CCI)
injury or to craniotomy control groups. The effects of treatment with synthetic, selective CB2R agonists (0-1966 and
JWH-133), a selective CB2R antagonist, or vehicle solution administered to CCI groups were assessed at 1-day after
injury. Changes in TNF-α, intracellular adhesion molecule (ICAM-1), inducible nitric oxide synthase (iNOS),
macrophage/microglial ionized calcium-binding adaptor molecule, and blood-brain-barrier (BBB) permeability were
assessed using ELISA, quantitative RT-PCR, immunohistochemistry, and fluorometric analysis of sodium fluorescein
uptake. CB2R knockouts and wild-type mice with CCI injury were treated with a CB2R agonist or vehicle treatment.
Results: TNF-α mRNA increased at 6 hours and 1 to 3 days after CCI; a CB2R antagonist and genetic knockout of
the CB2R exacerbated TNF-α mRNA expression. Treatment with a CB2R agonist attenuated TNF-α protein levels
indicating post-transcriptional mechanisms. Intracellular adhesion molecule (ICAM-1) mRNA was increased at 6 hours,
and at 1 to 2 days after CCI, reduced in mice treated with a CB2R agonist, and increased in CB2R knockout mice
with CCI. Sodium fluorescein uptake was increased in CB2R knockouts after CCI, with and without a CB2R agonist.
iNOS mRNA expression peaked early (6 hours) and remained increased from 1 to 3 days after injury. Treatment with
a CB2R agonist attenuated increases in iNOS mRNA expression, while genetic deletion of the CB2R resulted in
substantial increases in iNOS expression. Double label immunohistochemistry confirmed that iNOS was expressed
by macrophage/microglia in the injured cortex.
Conclusion: Findings demonstrate that the endogenous cannabinoid system and CB2R play an important role in
regulating inflammation and neurovascular responses in the traumatically injured brain. CB2R stimulation with
two agonists (0-1966 and JWH-133) dampened post-traumatic inflammation, while blockade or deletion of the
CB2R worsened inflammation. Findings support previous evidence that modulating the CB2R alters infiltrating
macrophages and activated resident microglia. Further investigation into the role of the CB2R on specific immune
cell populations in the injured brain is warranted.
Keywords: Controlled cortical impact, Traumatic brain injury, Cannabinoid, Inflammation, Intracellular adhesion molecule* Correspondence: Melanie.elliott@jefferson.edu
1Department of Neurological Surgery, Thomas Jefferson University Hospital,
1020 Locust Street, Thomas Jefferson University, Philadelphia, PA 19107, USA
Full list of author information is available at the end of the article
© 2014 Amenta et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Amenta et al. Journal of Neuroinflammation 2014, 11:191 Page 2 of 10
http://www.jneuroinflammation.com/content/11/1/191Introduction
Traumatic brain injury (TBI) affects over 1.4 million
Americans annually, with many suffering fatal or perman-
ently disabling injuries [1,2]. Blood-brain-barrier (BBB)
disruption, a result of the post-traumatic inflammatory re-
sponse, is a proposed mechanism of secondary injury and
contributes to cell death or dysfunction, worsening neuro-
logic function, and ultimately, to poorer clinical outcome
[3,4]. It is also well-recognized, however, that this same in-
flammatory response plays an important role in the pro-
cesses necessary for repair and recovery [5]. The initial
traumatic insult induces the release of pro-inflammatory
cytokines and chemokines triggering endothelial cell
activation, chemoattractant signaling, and immune cell
infiltration [6]. The release of TNF-α up-regulates the
expression of intracellular adhesion molecule-1 (ICAM-1),
which promotes the adherence of immune cells to the
endothelium and subsequent transmigration to sites of
inflammation [7]. The result of an inflammatory-driven
barrier breakdown is an enhancement of a cytotoxic en-
vironment in the setting of already compromised neu-
rons [8-10]. Infiltrating immune cells and resident microglia
have been shown to demonstrate opposing pro- and anti-
inflammatory phenotypes [11,12]. Pro-inflammatory cell
phenotypes release cytokines and express enzymes such
as inducible nitric oxide synthase (iNOS) that generate
damaging free radicals and further disrupt BBB func-
tion. Anti-inflammatory phenotypes produce cytokines
and growth factors that down-regulate free radical
generating pathways, which can promote healing and
regeneration. Optimal modulation of the post-traumatic
inflammatory response will limit damage and promote
reparative interactions between the immune and nervous
systems.
A number of cellular targets have been identified as po-
tential therapeutic interventions for the post-traumatic
inflammatory response. The endocannabinoid system, as
documented previously, represents a specialized group of
endogenous neurotransmitters with a broad range of func-
tion [13]. In particular, the cannabinoid receptor type-2
(CB2R), expressed predominantly by circulating immune
cells and resident microglia, plays an important role in the
immune response to injury. Upon stimulation with its lig-
and, the CB2R possesses potent immunomodulatory and
anti-inflammatory properties as reviewed by Cabral et al.
[14-18]. In a series of studies, stimulation of the CB2R has
been shown to dampen post-TBI inflammation including
infiltrating/resident immune cell activation and neurovas-
cular disruption, all of which were accompanied by im-
proved functional outcome following TBI and spinal cord
injuries [19-23]. These findings are supported by other la-
boratories, showing treatment with a CB2R agonist results
in immunomodulation and neuroprotection in models of
brain injury and neurodegeneration [18,24].Acute immunomodulation through CB2R ligands is
associated with improvements in outcome in animal
models of brain and spinal cord injury, Huntington’s dis-
ease, and Parkinson’s disease [18-20,22-25]. Emerging evi-
dence points to the modulation of microglia and infiltrating
macrophages as a key component in CB2R-mediated im-
provements in functional outcome. Furthermore, these
same immunomodulatory processes have also been impli-
cated as important moderators underlying the histopatho-
logic changes observed in cases of improved outcome
following injury [18,19,22-24,26,27]. Microglial activation
and inflammation in the traumatized brain can persist
for years after TBI [28,29], and like macrophages, express
pro-inflammatory (M1) and anti-inflammatory (M2) phe-
notypes [11,12,30]. A ‘loss of function’ in the M2 cell
phenotype may underlie chronic inflammation such as
occurs with traumatic brain injury [11]. Promoting the
healing function of M2 immune cells through CB2 recep-
tor stimulation may inhibit the detrimental effects of
long-term inflammation including synapse loss, neuronal
degeneration, and cognitive function [11]. The present
study further investigates the role of the CB2R in regulat-
ing acute inflammatory vascular responses to TBI using
CB2 receptor stimulation, blockade and deletion. We also
report the evidence linking CB2R stimulation and alter-
ation of the inflammatory cell phenotype.
Methods
Animal care and housing
Prior to initiating any research, the Thomas Jefferson
University Institutional Animal Care and Use Committee
(IACUC) reviewed and approved the research protocol
and the use of male C57BL/6 mice. Animal care and use
was monitored by the University Animal Care and Use
Committee to assure compliance with the provisions of
Federal Regulations and the NIH ‘Guide for the Care
and Use of Laboratory Animals’. All mice were housed
in the Thomas Jefferson University Laboratory Animal
Services Facility which is accredited by the American
Association for the Accreditation of Laboratory Animal
Care and complies with NIH standards.
Experimental design
Seventy-four (n = 74) adult male mice at approximately
8 weeks of age (weighing 22 to 24 g), including strains of
C57BL/6 wild-type mice (Charles River, Wilmington,
MA, USA) or CB2R knockout B6.129P2-Cnr2
tm1Dgen/J
mice (Taconic, Hudson, NY, USA) were randomly assigned
to undergo controlled cortical impact injury (n = 66) or
serve as craniotomy controls (control) (n = 8). There were
three study arms to determine the effects of CB2R modula-
tion on genes and proteins expression for primary vascular
inflammatory markers (TNF-α, ICAM, iNOS, and BBB
permeability) which included: (1) CCI injury over time
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tagonist compared to vehicle-treated mice, and (3) CB2R
knockout (CB2R KO) CCI groups with and without JWH-
133 compared to wild-type CCI (Figure 1). Endpoints for
CCI time course experiments were at either 6 hours (n = 4)
or 1 (n = 10), 2 (n = 7), or 3 (n = 5) days after CCI injury.
Two administrations of synthetic selective CB2R agonists,
0-1966 (n = 8) or JWH-133 (n = 12), a selective CB2R an-
tagonist, SR144528 (n = 4), or vehicle solution (n = 10)
were administered to wild-type CCI mice as described
below. To determine the selectivity for the CB2R, knock-
out mice lacking the CB2R were treated with a CB2R
agonist JWH-133 (n = 3) and 0-1966 (n = 4) or vehicle
(n = 9) and compared to wild-type CCI mice (n = 8).
Controls underwent all surgical procedures including an
equal time of isoflurane exposure, buprenorphine injec-
tion, incision and craniotomy but were not subjected to
CCI injury, did not receive treatment or vehicle, and were
euthanized at 3 days post-operatively. All surgeries and ex-
perimental post-mortem procedures were performed so
that, within each cohort of mice, craniotomy or vehicle-
treated control groups were run in parallel with their
respective experimental groups to insure consistent envir-
onmental conditions. On an annual basis, there is a 6 to
8% mortality rate for our CCI injury model due to the for-
mation of fatal hematomas or cerebrovascular blood clots.
Controlled cortical impact injury (CCI) injury resulted
in a loss of 6 of the original 66experimental CCI mice
(9% mortality rate) equally distributed among groups,
and final group sizes were reported for each experi-
mental outcome (see figures).Figure 1 Experimental design flowchart showing experimental group
arm: (1) CCI injured groups over time compared to craniotomy (contr
receptor type 2 (CB2R) agonist, (*0-1966 or **JWH-133 (JWH)), or CB2
vehicle or JWH, compared to CB2R knockout CCI injured mice with anTraumatic brain injury
Traumatic brain injury was induced using CCI injury, a
highly reproducible non-penetrating brain injury model
[31]. Mice were injured using methods previously de-
scribed by our laboratory [19,23,32]. Anesthesia was in-
duced with 3% isoflurane and maintained throughout the
procedure at a dose of 2.5% isoflurane. Prior to the start
of the procedure, all mice were injected with short-
acting buprenorphine (0.01 cc subcutaneous) for acute
post-operative pain control. A right-sided 4 mm craniot-
omy was performed at 1 mm posterior to bregma exposing
the mouse somatosensory cortex. A rounded aluminum
3 mm diameter stereotaxic impactor tip (MyNeuroLab, St.
Louis, MO, USA) was used to produce a cortical injury at
a 1.0 mm depth, 3 m/s velocity, and 100 msec contact
time. Following injury, the bone flap was sealed with
permanent cyanoacrylate-based fast-acting adhesive clo-
sures and the skin was closed with 6.0 silk sutures. Post-
operative care included warming with indirect heat from a
heat lamp until ambulation resumed, and unlimited access
to food and water. Brain and core body temperature were
maintained at 37 ± 0.5°C throughout the procedure and
monitored with temporalis muscle and rectal temperature
probes to avoid the neuroprotective effects of anesthesia-
induced hypothermia.
Treatment administration
Stimulation of the CB2 receptor was performed using ago-
nists 0-1966 (Organix Inc., Woburn, MA, USA) or JWH-133
(Tocris Bioscience, Minneapolis, MN, USA). 0-1966 was
used for the TNF and ICAM PCR experiments, whiles, endpoints, and outcome measures under each experimental
ol), (2) CCI injured mice treated with vehicle, cannabinoid
R antagonist (SR144528), and (3) wild-type CCI mice treated with
d without JWH.
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The CB2R agonist was switched to JWH-133 in the later
experiments in this study because it had the same se-
lectivity profile for CB2R as 0-1966 but with better solu-
bility, was easier to administer, and was commercially
available as a solution. 0-1966 was dissolved in a pure
ethanol:emulphor:normal saline solution (1:1:18) resulting
in a final concentration of 0.5 mg/mL. The CB2R agonist,
0-1966, also known as 0-1966A, is an analog of bicyc-
lic resorcinols (dimethoxy-resorcinol-dimethylheptyl) and
structurally similar to cannabidiol as described by Wiley
et al. [33]. 0-1966 demonstrates 225-fold higher selectivity
for the CB2R (Ki = 23 ± 2.1 nM) compared to CB1R (Ki =
5,055 ± 984 nM) [33]. JWH-133 selective CB2R agonist
(Ki = 3.4 nM), in water-soluble emulsion Tocrisolve TM
100 (Tocris Catalog Number 1684) has appoximately 200-
fold selectivity over CB1 receptors. The times for repeated
intraperitoneal (ip) injections of 0-1966 (5 mg/kg) and
JWH-133 (1 mg/kg) for the one-day endpoint were at ei-
ther 2 or 18 hours post-CCI. The timing of treatment ad-
ministrations were based on our previous studies [19].
Dosages were based both on preliminary dosing studies
performed by our laboratory for our TBI model as well
as on previous studies on models of stroke and spinal
cord injury [19-22,34]. Vehicle solution was prepared in
an identical manner to include 0.2 mL of pure ethanol:
emulphor:normal saline solution (1:1:18) minus the can-
nabinoid and administered at the same time points as 0-
1966. The selective CB2R antagonist, SR144528, (Cayman
Chemical, Ann Arbor, MI, USA) was dissolved in DMSO:
emulphor:normal saline solution (1:1:18) and injected at
5 mg/kg at 2 and 18 hours post-CCI.
BBB assessment
Fluid-phase BBB permeability was assessed using sodium
fluorescein (NaF) at 1 day post-CCI in wild-type, CB2R
KO mice with and without a CB2R agonist (JWH-133)
or controls as previously described by our laboratories
[8]. NaF uptake assay was performed for 20 mice ran-
domly divided into CCI subgroups euthanized at either
1 day (n = 236) or serving as controls (n = 4). CCI sub-
groups consisted of wild-type treated with vehicle or
JWH-133, and CB2R KO receiving vehicle or JWH-133.
Brain samples were run in duplicate experiments. We se-
lected NaF to evaluate changes in BBB permeability due
to its low molecular weight (376 Da) compared to others
probes that bind to albumin such as Evans Blue, horserad-
ish peroxidase (HRP), or IgG (≥67,000 Da). Thus, NaF is a
more sensitive probe that allows for detection of smaller
leaks in the barrier. Mice were injected ip with 100 μL of
10% NaF in PBS and the NaF was allowed to circulate
for 10 minutes. Following administration of a lethal dose
of sodium pentobarbital, cardiac blood was collected
followed by transcardial perfusion with 15 mL of heparin(1,000 U/L) in PBS. Brains were sectioned into a left and
right hemisphere and micro-dissected to separate the
cerebral cortex, and processed immediately. To determine
BBB permeability, tissues were weighed, homogenized in
1/10 dilution in PBS and centrifuged at 14,000 × g for
2 minutes. Five-hundred microliters of the clarified super-
natant was transferred into 500 μL of 15% trichloroacetic
acid and centrifuged at 10,000 × g for 10 minutes while
the pellet was retained for RNA isolation. One hundred
and twenty-five microliters of 5 N NaOH was added to
500 μL of the supernatant, and the amount of fluorescein
for each sample was determined using standards ran-
ging from 125 to 4,000 μg on a Cytofluor II fluorometer
(PerSeptive Biosystems, Framingham, MA, USA). Serum
levels of sodium fluorescein were assessed as previously
described so that signals in CNS tissue samples could be
normalized against the amount present in the circulation.
NaF uptake into each brain region of interest is expressed
as (ug/g NaF in cortex)/(μg NaF in serum).
RT-PCR
The pellet isolated during the BBB assessment outlined
above was subsequently used for RNA isolation. Total
RNA was extracted with the RNeasy Miniprep Kit (Qiagen,
Valencia, CA, USA), reverse transcribed into cDNA with
MMLV reverse transcriptase (Promega, Madison, WI,
USA) and then measured by quantitative real-time PCR
with gene-specific primers and probes [35]. IQ supermix
and the iCycler iQ real-time detection system were also
used for quantification (Bio-Rad Laboratories, Hercules,
CA, USA). All samples were run in duplicate and com-
pared to cDNA gene standards to determine copy num-
bers, which were normalized to the copy number of each
sample’s housekeeping gene L13. Levels of mRNA are re-
ported as the fold change in gene expression of normal-
ized to the endogenous reference gene L13 and relative to
the untreated, craniotomy controls.
Immunohistochemistry
Mice were administered a lethal dose of sodium pentobar-
bital (120 mg/kg, ip) and underwent cardiac perfusion
with heparinized saline followed by 4% paraformalde-
hyde. Brains were post-fixed in 4% paraformaldehyde for
24 hours, then transferred to 30% sucrose for storage. Fro-
zen sections were cut coronally with a cryostat at –24°C
(20 μm thick), and air dried overnight. Tissues were incu-
bated in 10% NGS in O.3% Triton-100. Coronal brain
sections were labeled using the following primary anti-
bodies overnight at room temperature: (1) rabbit anti-
mouse iNOS (1:200; Enzo Life Science, Farmingdale, NY,
USA) and (2) rabbit anti-mouse ionized calcium-binding
adaptor molecule-1 (Iba-1) (1:250; Wako Pure Chemical
Industries, Richmond, VA, USA). Fluorescent secondary
antibodies DyLight 488- or 549-conjugated AffiniPure
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PA, USA) were applied for 2 hours at room temperature.
Negative control staining was performed by omitting the
primary antibodies.
Statistical analyses
All statistical analyses were performed using the GraphPad
Prism 5 software program (La Jolla, CA, USA). To deter-
mine differences between CCI injury and controls at 6 hour,
2 day and 3 day time points, differences between wild-type
and knockout mice, and and differences between vehicle-
treated, agonist-treated, and antagonist-treated groups,
statistical comparisons were performed using a one-way
ANOVA followed by Bonferroni post hoc analysis for ex-
perimental groups compared to control. Significance levels
were set at P < 0.05 for all statistical analyses and results
are reported as the mean and SEM.
Results
TNF-α
The expression of mRNA specific for the pro-inflammatory
cytokine TNF-α was significantly increased by comparison
with controls at each time points examined after CCI
in wild-type mice including 6 hours (P < 0.05), 1 day
(P < 0.001), 2 and 3 days (P < 0.001) (Figure 2A and 2C).Figure 2 TNF-α mRNA in the injured cortex measured using quantitat
an enzyme-linked immunosorbent assay (D). (A) TNF-α mRNA at 6 hou
*P < 0.05 and ***P < 0.001. (B) TNF-α mRNA at 1 day after CCI injury in wil
receptor type-2 (CB2) agonist (0-1966) or CB2 receptor antagonist (SR14452
after CCI injury in CB2 knockout (CB2 KO) and wild-type mice compared to
(D) TNF-α protein concentration at 1 day post-CCI in vehicle-treated and C
respectively, **P < 0.01.Treatment with a CB2R antagonist, SR144528, signifi-
cantly increased TNF-α mRNA expression at 1 day post-
CCI (ANOVA P < 0.0001, F = 23.00), but mRNA levels
where not altered after administration of a CB2R agonist,
0-1966 (Figure 2B). The increase in TNF-α mRNA medi-
ated by the antagonist are paralleled by genetic deletion of
the CB2R at one day post-CCI compared to control (P <
0.001) and wild-type mice, P < 0.01 (Figure 2C). As shown
in Figure 2D, the elevation in the levels of TNF-α protein
at 1 day following CCI were reduced by CB2R agonist
treatment (Figure 2D).
ICAM
Increases in intracellular adhesion molecule-1 (ICAM-1)
induced by increases in TNF-α were expected to occur
in the first few days after injury when macrophage and
microglial infiltration to the injured site peaks. ICAM
mRNA was found to be significantly increased in the in-
jured cortex at 6 hours, 1 and 2 days compared to controls
ANOVA P < 0.05 (Figure 3A and 3C). ICAM mRNA ex-
pression returned to control levels by 3 days after injury.
Administration of a 0-1966 significantly reduced ICAM-1
mRNA at one day post-CCI (ANOVA P < 0.01 and F =
9.53), while treatment with a CB2R antagonist, SR144528,
did not change mRNA levels (Figure 3B). CCI inductionive real-time PCR (A-C) and TNF-α protein concentration using
rs, 2 and 3 days after CCI injury compared to craniotomy (control),
d-type mice treated with a vehicle solution (vehicle), cannabinoid
8) compared to vehicle control, ***P < 0.001. (C) TNF-α mRNA at 1 day
control, ***P < 0.001, and ##P < 0.01 compared to wild-type mice.
B2 agonist-treated (JWH-133) mice compared to control and vehicle,
Figure 3 Intracellular adhesion molecule (ICAM) mRNA expression in the injured cortex measured using quantitative real-time PCR.
(A) ICAM mRNA at 6 hours, 2 and 3 days after CCI injury compared to control, *P < 0.05. (B) ICAM mRNA at 1 day after CCI injury in wild-type
mice treated with a cannabinoid type-2 (CB2) agonist (0-1966) and CB2 antagonist (SR144528) compared to vehicle-treated CCI controls, **P < 0.01.
(C) ICAM mRNA at 1 day after CCI injury in CB2 knockout (CB2 −/−) mice and wild-type mice compared to control, **P < 0.01 and ***P < 0.001;
ICAM mRNA post-CCI in CB2 knockout (CB2 −/−) mice compared to wild-type mice, #P < 0.05.
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cantly increased ICAM-1 mRNA expression at 1 day post-
CCI compared to wild-type mice with and without CCI
(ANOVA P < 0.001 F = 16.63) (Figure 3C).
BBB permeability
BBB permeability was assessed by sodium fluorescein
(NaF) uptake into the injured cortex (Figure 4). Treat-
ment with JWH-133 reduced the injury-induced increase
in NaF uptake, P < 0.05. NaF uptake was significantly in-
creased in CCI injured CB2R KO mice treated with the
CB2R agonist or vehicle (P < 0.05; P < 0.01) when com-
pared to CCI-injured wild-type mice. The receptor se-
lectivity of the agonist at the BBB was demonstrated as
CB2R KO mice treated with CB2R agonist, JWH-133,
were not different from CB2R KO mice treated with ve-
hicle control.
iNOS
iNOS mRNA was significantly increased in the injured
cortex at 6 hours, 1 day, 2, and 3 days after injury (P <
0.001; F = 10.57) compared to controls (Figure 5A). In-
creased iNOS mRNA expression in vehicle-treated miceFigure 4 Blood-brain-barrier permeability assessment using
sodium fluorescein (NaF) uptake in the injured cortex. NaF
uptake for wild-type CCI injured mice treated with vehicle compared
to JWH-133 (JWH), *P < 0.05 and cannabinoid type-2 knockout CCI
mice (CB2R KO) treated with vehicle or JWH, **P < 0.01 compared to
wild-type vehicle-treated CCI mice (vehicle).at 1 day post-CCI was attenuated by treatment with a
CB2R agonist (JWH-133) ANOVA P < 0.001 and F =
38.35 (Figure 5B). Interestingly, CCI injury in knockout
mice lacking the CB2R resulted in a considerable in-
crease in iNOS mRNA levels (nearly 10-fold increase) in
the injured cortex than in CCI injured wild-type mice
(ANOVA P < 0.0001 and F = 20.67). Treatment with ag-
onists JWH-133 and 0-1966 reduced the levels of iNOS
in CB2R KO mice indicating mechanisms other than the
CB2R are involved in the agonist’s actions in the injured
parenchyma.
Immunohistochemical double labeling for iNOS and a
macrophage/microglial specific marker, ionized calcium-
binding adaptor molecule (IBA-1) was used to qualita-
tively evaluate the cellular source of iNOS in the injured
cortex (Figure 6). Cells within the cortical tissue sur-
rounding the contusion that were positive for iNOS were
co-labeled as macrophage/microglia cells. Some iNOS
positive cells were also found distal to the injury in the
cingulate cortex and subcortical areas; however, these
cells did not co-localize with IBA-1 and showed a neur-
onal morphology (not shown).
Discussion
Previously, our laboratory found CB2R stimulation re-
duced BBB permeability and decreased the number of
macrophage/microglia in mice with controlled cortical
injury [19,23]. We now show that early treatment with a
CB2R agonist reduces the post-traumatic increase in intra-
cellular adhesion molecule (ICAM-1) mRNA expression
after TBI. This effect is accompanied by reduced levels of
TNF-α protein. Conversely, genetic deletion of the CB2R
increased the expression of ICAM-1 and TNF-α mRNA
and exacerbated the BBB permeability that follows TBI.
Pharmacological blockade of the CB2R with an antagonist
also increased the levels of TNF-α mRNA. CB2R stimula-
tion improved BBB integrity after TBI, likely secondary to
an attenuation of endothelial cell, macrophage, and micro-
glia activation [19,23]. The failure of the CB2R agonist to
impact these barrier responses in mice lacking the CB2R
Figure 5 Inducible nitric oxide synthase (iNOS) mRNA in the injured cortex. (A) iNOS mRNA at 6 hours, 1 and 3 days after CCI injury
compared to control, *P < 0.05, **P < 0.01, and ***P < 0.001. (B) iNOS mRNA at 1 day after CCI injury in mice compared to control, P < 0.001, and CCI
mice treated with JWH-133 (JWH) compared to vehicle, ###P < 0.001. (C) iNOS mRNA in CB2 knockout (CB2 KO) mice compared to wild-type mice at
1 day after CCI injury, ***P < 0.001, and CB2 KO treated with JWH and 0-1966 (1966) compared to CB2 KO mice ###P < 0.001.
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ipherally or at the blood-brain interface, is selective for the
CB2R. Interesting and not entirely surprising findings were
that both CB2R agonists in CB2R KO mice showed similar
effects in reducing iNOS mRNA after injury. This finding
indicates the involvement of a non-CB2 receptor, although
due to the low affinity for the CB1 receptor, activation of
the CB1 receptor is unlikely to be involved but cannot be
completely ruled out. JWH-133 improved cerebral infarc-
tion but the effect was absent in CB2R KO mice. [24]. Al-
though there is some overlap between secondary injury
mechanisms for stroke and traumatic brain injury, they
are in fact distinguishable. CB2R selective effects on cell
infiltration and BBB permeability make a different contri-
bution to the damaged brain in stroke compared to TBI.
We conclude that the effects of the drug appear to have
CB2R selectivity peripherally and at the BBB interface;
however, once penetrating the brain, there may be non-
CB1 and non- CB2 receptors involved. Synthetic CB1/CB2
receptor ligands can interact with non-CB1R, non-CB2 G
protein-coupled receptors, transmitter gated channels, ion
channels and/or nuclear receptors and is reviewed by
Pertwee et al. [36]. While the G protein-coupled receptor
GPR55 and potassium channels have been excluded from
the actions of JWH-133, others have not yet been eluci-
dated. These findings provide additional support for the
concept that the endogenous cannabinoid system facilitatesFigure 6 Macrophage/microglial marker, Iba-1, and inducible nitric ox
cortical area adjacent to the contusion. Image shows (A) Iba-1 positive
showing Iba-1 co-localized with iNOS positive cells with a retracted, amoebprotection against secondary injury following TBI [37,38],
and that the neuroprotective effects of CB2R stimulation
are due, in part, to the modulation of intracranial micro-
vascular function leading to attenuated immune cell infil-
tration. Similar effects have been reported in studies of
ischemic brain injury, whereby reductions in immune cell
trafficking accompanied CB2R agonist-induced decreases
in ICAM-1 expression and BBB damage [20,21,34]. More-
over, following exposure to a variety of inflammatory
stimuli, CB2R stimulation increased endothelial cell tight
junction protein expression in the brain microvasculature
and reduced vascular permeability and the expression of
ICAM-1 and VCAM-1 [39]. Finally, genetic knockout of
the CB2R has been shown to worsen inflammation, injury
and behavioral deficits in several models of CNS diseases
[18,20,25,39]. These findings indicate the importance of
the CB2R in regulating the immune and vascular response,
as well as recovery following injury to the brain.
Early, rapid and robust production of pro-inflammatory
cytokines, such as TNF-α after TBI, is responsible for the
upregulation of ICAM-1 expression and subsequent im-
mune cell infiltration to the injured brain [7,40]. TNF-α is
a key cytokine that has been implicated in the induction
of pathological inflammation in a variety of models includ-
ing TBI. The finding that TNF-α expression following CCI
is strongly elevated by administration of a CB2 antagonist
together with its increase in CB2 knockout mice subject toide synthase (iNOS) immunofluorescence in the remaining
cells (green), (B) iNOS positive cells (red), and (C) merged image
oid morphology (yellow).
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trolling TNF-α expression after TBI. The lack of changes
in TNF message transcription with CB2R stimulation in
this study may be secondary to the post-CCI time point
examined. Treatment with a CB2R agonist reduced TNF-
α mRNA at 15 hours after middle cerebral artery occlu-
sion [24]. Fluctuations in TNF-α protein levels have been
reported hours to days after CCI injury [41-43]. Cyclical
changes in cytokine genes including TNF-α have also been
shown after CCI injury in mice [6]. TNF-α mRNA fluctu-
ates over time after injury, in which the levels, albeit in-
creased compared to controls, were at the lowest level at
the 1 day time point.
It is important to note that the TNF-α protein levels
were reduced by CB2R agonist treatment. This suggests
additional post-transcriptional or post-translational mech-
anisms may be involved in attenuating the expression
of TNF-α protein. Post-transcriptional modification of
RNA ultimately determines expression levels by modulat-
ing mRNA stability, transport, and translation efficiency.
Several key post-transcriptional regulatory elements
include RNA-binding proteins, kinases and phosphatases,
degradation enzymes, Au-Rich elements (AREs) and micro-
RNA (miRNA). RNA-binding proteins can silence (or fa-
cilitate) the translation of TNF mRNA. For example,
RNA-binding proteins, T-cell intracellular Ag (TIA-1)
and TIA-1-related protein (TIAR), both silence TNF
mRNA [44]; kinases and phosphatases change the binding
efficiency of RNA-binding proteins and AREs sites. CNS
injury alters the mitogen-activated protein kinase (MAPK)
pathway enhancing mRNA stability and the efficacy of
inflammatory cytokine generation. Interestingly, a CB2R
agonist was shown to reduce spinal MAPKs (p38 and
p-ERK-1/2) through increased expression of mitogen-
activated protein kinase phosphatases (MKP-1 and MKP-3)
in primary microglial cells [45] and may explain the reduc-
tion in TNF-α protein expression in this study. Addition-
ally, post-translational processes that interfere with the
release of soluble TNF-α from its membrane-anchored
pre-cursor or promote degradation of the protein may
be involved.
Circulating leukocytes infiltrate the brain after cortical
injury, reaching maximal accumulation 2 to 3 days after
injury [19,23,46,47], which coincides with increases in
barrier permeability [23]. ICAM-integrin interactions, in
particular, are important for leukocyte adhesion and
transendothelial migration to the injured brain. ICAM-1
(CD54) is a cell surface ligand that binds the integrins
lymphocyte function-associated antigen-1 (LFA-1, CD11a/
CD18) and macrophage adhesion molecule (Mac-1, CD
11b/CD 18) [7]. After TBI, increased expression of
endothelial ICAM-1 helps to precisely guide the migration
of leukocytes to the site of injury [43,48,49]. Increased
expression of ICAM-1 is tightly coupled with changes inmacrophage/microglia activation after CCI injury [49]. Past
and present findings by our laboratory support the notion
that stimulation of the CB2R attenuates the inflammatory
vascular response to injury. ICAM mRNA levels showed a
peak at the 1-day time point that was influenced by the
CB2R deletion but not synthetic blockade. Results indicate
a more pronounced effect on the immune-vascular injury
response by genetically modifying the endogenous CB re-
ceptor system. The process of immune cell infiltration into
the damaged parenchyma also enhances the permeability
of the BBB. At the site of injury, microglia and accumulat-
ing immune cells release pro-inflammatory mediators and
free radicals, both of which are known to disrupt the
neurovascular unit, compromise the integrity of the BBB,
and contribute to excitotoxicity and cell toxicity [8,50,51].
Disruption of the BBB is especially relevant to TBI as it is a
proposed secondary injury mechanism creating a cytotoxic
environment for neurons [52,53].
Stimulation of the CB2R suppresses activation, chemo-
taxis, and migration of peripheral macrophages, monocytes,
and T cells, as well as microglial-like cells [15,16,54-58].
These observations suggest that a number of cell types asso-
ciated with CNS inflammation express the CB2R. Insults to
the CNS and pro-inflammatory conditions have been found
to result in significant upregulation of CB2R mRNA expres-
sion [13]. CB2R mRNA expression is increased 10-fold by
activation of microglia and peripheral macrophages in cul-
ture [59]. While there is general agreement that circulating
immune cells and microglia express the CB2R, a controversy
exists over the expression of the CB2R on other CNS cell
types [14,59-62]. Evidently, this is due to differences in the
antibodies used for immunohistochemistry between groups.
Distinctions in the role of infiltrating macrophages and
resident microglia in brain injury continues to be a chal-
lenge as these cells are both of a monocyte lineage and
express many of the same cell-surface markers. Adding to
the complexity, is the growing evidence that macro-
phages and microglia are capable of expressing both
pro-inflammatory (M1) and anti-inflammatory (M2)
phenotypes [11,12,30]. In addition to pro-inflammatory
cytokines and adhesion molecules, iNOS is another marker
expressed by a M1 cell phenotype and is useful to study
these phenotype differences and injury mechanisms. CB2R
stimulation significantly reduced iNOS mRNA, while
genetic deletion substantially exacerbated iNOS expression.
Moreover, qualitative analysis of the remaining cortical
tissue surrounding the injury showed iNOS expression to
be predominantly from a macrophage/microglia cellular
source. In a model of TBI, results suggest that the protec-
tion offered by a microglial inhibitor, minocycline, may be
through cannabinoid receptors as well [63]. Results suggest
that selective modulation of the CB2R transforms the
inflammatory phenotype of the infiltrating and/or immune
cells after injury.
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Modification of the inflammatory vascular responses to
TBI through CB2R stimulation, as well as receptor blockade
and deletion demonstrate the importance of this receptor
in recovery from TBI. The CB2R is an endogenous regula-
tor of the inflammatory response to TBI, working at the
interface between the brain and microvasculature. Macro-
phage/microglial modulation using CB2R agonists has a
significant contribution to its protective capabilities
[18,24,25]. Interventions that limit prolonged microglial
activation and neuroinflammation as occurs after TBI,
or facilitate a reparative microglial phenotype are pro-
posed to counteract the development of cognitive and
affective disorders [30]. Our results further support that
CB2R-dependent pathways regulate the bridge between
immune and vascular function following TBI. The devel-
opment of pharmacological agents to treat TBI may rest
in furthering our understanding of the complex immune,
vascular, and nervous system interactions that are induced
at the time of injury.
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